Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Neuroinflammation in Alzheimer's disease in 'PubMed', 14 April 2015
Heneka MT1, Carson MJ2, El Khoury J3, Landreth GE4, Brosseron F5, Feinstein DL6, Jacobs AH7, Wyss-Coray T8, Vitorica J9, Ransohoff RM10, Herrup K11, Frautschy SA12, Finsen B13, Brown GC14, Verkhratsky A15, Yamanaka K16, Koistinaho J17, Latz E18, Halle A19, Petzold GC20, Town T21, Morgan D22, Shinohara ML23, Perry VH24, Holmes C25, Bazan NG26, Brooks DJ27, Hunot S28, Joseph B29, Deigendesch N30, Garaschuk O31, Boddeke E32, Dinarello CA33, Breitner JC34, Cole GM12, Golenbock DT35, Kummer MP36.

Excerpts:
"External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease."

Article at:
http://www.ncbi.nlm.nih.gov/pubmed/25792098